Cerebrovascular muscle atrophy is a feature of Alzheimer's disease. (Q48447589)

11 February 2018

title

Cerebrovascular muscle atrophy is a feature of Alzheimer's disease. (English)

1 reference

11 February 2018

0 references

1

G Perry

1 reference

11 February 2018

M A Smith

2

1 reference

11 February 2018

C E McCann

3

1 reference

11 February 2018

S L Siedlak

4

1 reference

11 February 2018

P K Jones

5

1 reference

11 February 2018

R P Friedland

6

1 reference

11 February 2018

language of work or name

English

0 references

publication date

1 April 1998

1 reference

11 February 2018

published in

Brain Research

1 reference

11 February 2018

volume

791

1 reference

11 February 2018

issue

1-2

1 reference

11 February 2018

page(s)

63-66

1 reference

11 February 2018

Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900006-7

Hirano body filaments contain actin and actin-associated proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900006-7

Clinically diagnosed Alzheimer's disease: autopsy results in 150 cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900006-7

Degeneration of vascular muscle cells in cerebral amyloid angiopathy of Alzheimer disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900006-7

Diagnosis of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900006-7

Cerebral metabolic and cognitive studies in dementia with frontal lobe behavioral features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900006-7

The incidence of cerebral amyloid angiopathy in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900006-7

Oxidative stress hypothesis in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900006-7

Mechanisms of neurotoxicity associated with amyloid beta deposition and the role of free radicals in the pathogenesis of Alzheimer's disease: a critical appraisal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900006-7

The amyloid beta-protein precursor is localized in smooth muscle cells of leptomeningeal vessels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900006-7

Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900006-7

Radical AGEing in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900006-7

Oxidative damage in Alzheimer's.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900006-7

Widespread peroxynitrite-mediated damage in Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900006-7

Brain infarction and the clinical expression of Alzheimer disease. The Nun Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900006-7

Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900006-7

10.1016/S0006-8993(98)00006-7

7 January 2021

Identifiers

DOI

1 reference

11 February 2018

PubMed ID

9593825

1 reference

11 February 2018